insurance changes to glp-1 drugs Trends: Access & Shortages, Coverage & More glp-1 insurance coverage for weight

PMID: 76

A.BouchaudC.et al (1996)

This approach requires very careful monitoring by an experienced medical professional

ACE inhibitors + ARBs Double-suppress the RAA system from upstream and downstream There are cases where proteinuria and blood pressure decrease further There is little additional long-term cardio-renal outcome Hyperkalemia, hypotension, acute kidney injury, etc., increase The problem is not just insufficient effect, but an increase in harm GLP-1 receptor agonists + DPP-4 inhibitors Stimulate the same incretin pathway repeatedly There is a possibility that active incretins will increase There is little clinical addition to blood glucose and body weight Serious harm specific to the combination has not been clearly proven The main problem is that the efficiency as a treatment is poor In other words, ACE inhibitors + ARBs = there is little additional effect, and harm increases GLP-1 receptor agonists + DPP-4 inhibitors = there is little additional effect, and there is almost no point in using it is the difference